✦ LIBER ✦

Interpreting the Clinical Significance of Capacity Scores for Informed Consent in Alzheimer Disease Clinical Trials

✍ Scribed by Karlawish, Jason; Kim, Scott Y.H.; Knopman, David; van Dyck, Christopher H.; James, Bryan D.; Marson, Daniel

Book ID: 122422832
Publisher: American Psychiatric Publishing Inc
Year: 2008
Tongue: English
Weight: 92 KB
Volume: 16
Category: Article
ISSN: 1064-7481
DOI: 10.1097/JGP.0b013e318172b406

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Role of Biomarkers in Clinical Trial

The Role of Biomarkers in Clinical Trials for Alzheimer Disease

✍ Thal, Leon J; Kantarci, Kejal; Reiman, Eric M; Klunk, William E; Weiner, Michael 📂 Article 📅 2006 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 306 KB

Interpreting Alzheimer’s disease clinica

Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β

✍ Jeremy H Toyn,Michael K Ahlijanian 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 277 KB

The Views of Alzheimer Disease Patients

The Views of Alzheimer Disease Patients and Their Study Partners on Proxy Consent for Clinical Trial Enrollment

✍ Karlawish, Jason; Kim, Scott Y.H.; Knopman, David; van Dyck, Christopher H.; Jam 📂 Article 📅 2008 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 95 KB

Procedure of informed assent/consent for

Procedure of informed assent/consent for clinical trials in pediatric hemato-oncology: The adolescents' and parents' point of view

✍ Van de Velde, V.; De Strooper, E.; Morez, A.; Van Broeck, N.; Laureys, G.; Benoi 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 133 KB

The ADAS-cog and clinically meaningful c

The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease

✍ Kenneth Rockwood; Sherri Fay; Mary Gorman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

## Abstract ## Background A minimum 4‐point change at 6 months on the Alzheimer's disease assessment scale‐cognitive subscale (ADAS‐cog) is deemed clinically important, but this cut‐point has been little studied in relation to clinical meaningfulness. In an investigator‐initiated, clinical trial o

Minimal clinically significant change fo

Minimal clinically significant change for the International Restless Legs Syndrome Study Group rating scale in clinical trials is a score of 3

✍ Allen, Richard P. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 174 KB